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Background: Atrial fibrillation is very common in people aged 65 or older. This condition increases the risk of
death, congestive heart failure and thromboembolic conditions. Many patients with atrial fibrillation are
asymptomatic and a cerebrovascular accident (CVA) is often the first clinical presentation. Guidelines concerning
the prevention of CVA recommend monitoring the heart rate in patients aged 65 or older. Recently, the
MyDiagnostick (Applied Biomedical Systems BV, Maastricht, The Netherlands) was introduced as a new screening
tool which might serve as an alternative for the less accurate pulse palpation. This study was designed to explore
the diagnostic accuracy of the MyDiagnostick for the detection of atrial fibrillation.
Methods: A phase II diagnostic accuracy study in a convenience sample of 191 subjects recruited in primary care.
The majority of participants were patients with a known history of atrial fibrillation (n = 161). Readings of the
MyDiagnostick were compared with electrocardiographic recordings. Sensitivity and specificity and their 95%
confidence interval were calculated using 2x2 tables.
Results: A prevalence of 54% for an atrial fibrillation rhythm was found in the study population at the moment of
the study. A combination of three measurements with the MyDiagnostick for each patient showed a sensitivity of
94% (95% CI 87 – 98) and a specificity of 93% (95% CI 85 – 97).
Conclusion: The MyDiagnostick is an easy-to-use device that showed a good diagnostic accuracy with a high
sensitivity and specificity for atrial fibrillation in a convenience sample in primary care. Future research is needed to
determine the place of the MyDiagnostick in possible screening or case-finding strategies for atrial fibrillation.
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Atrial fibrillation is currently the second most frequently
occurring cardiac arrhythmia in clinical practice (after
extrasystole). Its prevalence is estimated around 0.4 –
1.0% in the general population, increasing with age, up
to 5.0 – 6.0 in those aged 65 or older and 8.0% in sub-
jects aged 80 or older [1].
More than 30% of patients with atrial fibrillation are
asymptomatic. Furthermore, this condition increases the
risk of death, congestive heart failure and thrombo-
embolic conditions [2,3]. The risk of cerebrovascular* Correspondence: Bert.Vaes@uclouvain.be
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unless otherwise stated.accident (CVA) even increases fivefold in case of atrial
fibrillation and CVA is often the first clinical presenta-
tion of atrial fibrillation. Moreover, the risk for CVA in-
creases with increasing age; from 9.9% in patients
between 70 – 79 years to 24% in the group of patients
between 80 – 89 years [4-6].
The current European guidelines on atrial fibrillation
emphasize the importance to start anticoagulation in
order to decrease the risk of CVA [6]. In order to assess
this risk, the CHADS2 score is used, along with the more
recent and more accurate CHA2DS2VASc score [7,8].
Therefore, the high prevalence of atrial fibrillation, the
potentially serious consequences of the condition, the
presence of effective therapy and the minimal impact of
treatment on the quality of life of the patient ensure thatd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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or should be done [9].
Guidelines concerning the prevention of CVA recom-
mend monitoring the heart rate in patients aged 65 or
older, followed by electrocardiogram (ECG) monitoring
in case of an irregular rhythm [6,10]. Palpation of the
pulse, to monitor the heart rate, has a good sensitivity
but a low specificity, making this a useful method of rul-
ing out atrial fibrillation but a less good method of con-
firming it [11]. Recently, the MyDiagnostick (Applied
Biomedical Systems BV, Maastricht, The Netherlands)
[12] was introduced as a new screening tool and an al-
ternative for the less accurate pulse palpation. This de-
vice has the form of a rod with a metal handle on both
ends. There are electrodes in these handles making it
possible to record a single-lead ECG (Figure 1). This
new screening technique would facilitate home screen-
ing and increase the likelihood of detection of asymp-
tomatic atrial fibrillation.
Therefore, this study was designed to explore the diag-




Participating general practitioners were asked to invite
patients with known, paroxysmal or chronic atrial fibril-
lation to participate in the study. Furthermore, this con-
venience sample was added up with subjects without a
history of atrial fibrillation. With the probability of find-
ing a false positive result of 5% or less (α = 0.05), an esti-
mated prevalence of atrial fibrillation of 50% in the
study population, an expected sensitivity and specificity
of 95% and a confidence interval of 4%, a sample size of
160 subjects was needed [13]. To end up with a preva-
lence of atrial fibrillation of at least 50% at the moment
of the study the vast majority of the invited patients
were people with a known history of atrial fibrillation
(161/191) and only 30 people without a history of atrialFigure 1 The MyDiagnostick device.fibrillation. The patients who were willing to take part in
the survey were given an appointment for an examin-
ation by the research team in their own general practice
centre. Before participating in the study, all patients
signed an informed consent. The study was approved by
the ethical review board of the Medical Faculty of the
Catholic University of Leuven, Belgium (no ML 10464).
Patients wearing a pacemaker were excluded if the pace-
maker was configured in active pacing mode.
Clinical characteristics were registered by the re-
searcher (SS, KT, BT or DL). The body mass index was
calculated, the blood pressure measured and a limited
number of comorbidities extracted from the electronic
medical record. The presence of diabetes mellitus type
II, arterial hypertension and peripheral arterial illness
and a history of coronary heart disease and transient is-
chaemic attack or CVA was reported and the CHA2DS2
VASc score for each participant calculated. The intake of
platelet aggregation inhibitors or anticoagulants (war-
farin or new oral anticoagulants) was registered.
A trial fibrillation
Each participant was tested with the MyDiagnostick
(Applied Biomedical Systems BV, Maastricht, The
Netherlands) [12] by a single researcher who was not
blinded for the medical history of the patient. This de-
vice has the form of a rod with a metal handle on both
ends. In these handles electrodes make it possible to rec-
ord a single-lead ECG that is analyzed automatically.
The patient was asked to grasp the device by both han-
dles. After one minute the ECG lead was analysed and
LED indicators gave a red or green signal that could be
interpreted as the presence or absence of atrial fibrilla-
tion. Three consecutive recordings with the MyDiagno-
stick with a 1 – 2 minute interval were done. Figure 2
shows single-lead ECGs provided by the MyDiagnostick.
The MyDiagnostick has a storage capacity of 140 record-
ings of 50 – 70 seconds.
The method of detection of AF in the MyDiagnostick
is based on the measurement of R-R interval irregularity.
Prior AF detection, the acquired ECG (1 minute) is pre-
processed and R-waves are detected. From all detected
R-wave annotations, R-R intervals are computed and
used as an input for AF detection. The AF algorithm cal-
culates an overall AF score based on a base rhythm-,
periodicity- and variability score. The base rhythm score
is based on a normal sinus rhythm state-machine chain-
ing normal R-R intervals, including occasional prema-
ture intervals and short runs of tachycardia. Creation of
long chains reflects a fit of the sinus rhythm state-
model, lowering the probability of AF. The periodicity
and variability scores are based on the R-R autocor-
relation function. Periodicity of R-R interval patterns
will generate multiple correlation peaks, whereas R-R
Sinus rhythm
Atrial fibrillation
Figure 2 Single-lead ECGs provided by the MyDiagnostick (sinus rhythm and atrial fibrillation).
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small shift. The overall AF score is obtained by linear
combination of all scores and compared to a thresh-
old, producing a dichotomous result (AF/no AF).
Afterwards a 12-lead electrocardiogram (ECG) (gold
standard) was carried out once by the same researcher.
The ECGs were done using digital machines (HeartScreen
80 G-L (MediSafe Ltd, Winchester, United Kingdom),
Welch Allyn CP 50 (Welch Allyn, New York, USA),
Nihon Kohden Cardiofax S 1250 (Nihon Kohden,
Tokyo, Japan) or Schiller AT101 (Schiller AG, Baar,
Switzerland)) and the data were immediately printed.
The ECGs were analyzed off-line on the basis of the
Minnesota Code Classification System for Electrocar-
diographic Findings [14] (code 8-3-1) by an experienced
cardiologist (WM), blinded for the software interpret-
ation and the results from the MyDiagnostick.
The readings of the MyDiagnostick were compared with
the electrocardiographic recording. The overall three mea-
surements on the MyDiagnostick were viewed for each
patient. A green light three times was interpreted as a
negative result and a red light three times as a positive re-
sult. The non-uniform results of the MyDiagnostick were
interpreted in favour of the most common outcome (i.e.
2x red and 1x green was interpreted as a positive result,
while 1x red and 2x green was interpreted as a negative
result).Statistical analysis
Sensitivity and specificity and their 95% confidence
interval were calculated using 2x2 tables (MedCalc®
11.6.0.0 (Mariakerke, Belgium)). The positive and nega-
tive predictive values were then estimated based on anexpected prevalence of atrial fibrillation of 6% in the
population aged 65 or older.
Results
A total of 191 subjects participated in this study of
which 91 (48%) women. The mean age of the partici-
pants was 74.6 ± 9.7 years (range 50 – 99 years). In total
30 participants without a history of atrial fibrillation (all
in sinus rhythm on ECG) and 161 participants that were
known to have paroxysmal or chronic atrial fibrillation
were included (Figure 3). Of these latter subjects, 103
showed atrial fibrillation on their ECG at the moment of
the study. Thus, a prevalence of 54% for an atrial fibrilla-
tion rhythm was found in the study population. Table 1
shows the patient characteristics according to the pres-
ence of atrial fibrillation. A pacemaker was present in 17
participants, in 10 patients the pacemaker was active at
the moment of the ECG recording and they were there-
fore excluded from further analysis. The analysis was
continued with 181 participants (prevalence of atrial fib-
rillation, 53%).
The MyDiagnostick showed a positive result in 96 par-
ticipants and a negative result in 85 subjects (Table 2).
No unsuccessful attempts were reported. In the event of
a uniform result (n = 166, 92%) the diagnosis was correct
in 96% of cases (seven misdiagnoses, four false positives
and three false negatives). A total of 15 participants
showed non-uniform results (nine positive results, and
six negative results), in which 10 participants were inter-
preted correctly (seven true positives and three true neg-
atives) and five were misinterpreted. On the basis of
these results sensitivity for the MyDiagnostick of 94%
(95% CI 87–98) and a specificity of 93% (95% CI 85–97)
was obtained. Based on an expected prevalence of 6% in
Total study population
n = 191
History of paroxysmal or 
chronic atrial fibrillation
n = 161
Atrial fibrillation at the 
moment of the study
n = 103
Sinus rhythm at the 
moment of the study
n = 88












No or inactive 
pacemaker
n = 85
Figure 3 Flow chart of study participants.
Table 1 Characteristics of the study population (n = 191)
Atrial fibrillation present Atrial fibrillation absent
(n = 103) (n = 88)
Age, mean ± SD 77 ± 8 71 ± 11
Male gender, n (%) 57 (55.3) 43 (51.1)
BMI, mean ± SD 27.7 ± 6.9 25.9 ± 6.5
Systolic blood pressure, mean ± SD 130 ± 19 130 ± 18
Diastolic blood pressure, mean ± SD 75 ± 14 75 ± 10
CHA2DS2VASC score, median (IQR) 3 (2 – 4) 3 (2 – 3)
Comorbidity
Diabetes mellitus type II, n (%) 26 (25.2) 15 (17.0)
Arterial hypertension, n (%) 94 (91.3) 62 (70.5)
Coronary heart disease, n (%) 9 (8.7) 16 (18.2)
TIA or CVA, n (%) 17 (16.5) 4 (4 .5)
Peripheral arterial illness, n (%) 4 (3.9) 4 (4.5)
Anticoagulation
No anticoagulation, n (%) 0 (0) 22 (25.0)
Platelet aggregation inhibitor, n (%) 6 (5.8) 24 (27.3)
Warfarin, n (%) 69 (67.0) 30 (34.1)
New oral anticoagulants, n (%) 28 (27.2) 12 (13.6)
SD: standard deviation; IQR: inter-quartile range; TIA: transient ischaemic attack; CVA: cerebro-vascular accident.
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Table 2 2x2 table to calculate the diagnostic accuracy of the MyDiagnostick
Atrial fibrillation present Atrial fibrillation absent Total
MyDiagnostick positive result 90 6 96
MyDiagnostick negative result 6 79 85
Total 96 85 181
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value of 45% (95% CI 24 – 68) and a negative predictive
value of 99% (95% CI 97 – 100) were estimated.
Discussion
In this study of a convenience sample in primary care,
the MyDiagnostick was able to accurately set the diagno-
sis of atrial fibrillation with a high sensitivity and specifi-
city. The sensitivity measures the proportion of actual
positives that have been correctly identified and the spe-
cificity measures the proportion of the actual negatives
that have been appropriately recognized as such. These
two measures are closely related to the concepts of type
I (a test that shows a patient to have a disease when in
fact the patient does not have the disease) and type II
(a test that shows a patient not to have a disease when
the patient does have the disease) errors. A perfect diag-
nostic test would be 100% sensitive (no false negatives)
and 100% specific (no false positives). However, in a low
prevalence setting like primary care and for possible
screening purposes the sensitivity of a test, the capacity
to rule out the disease, could be considered as the most
important measure.
The results for the MyDiagnostick are in line with the
diagnostic accuracy found for other screening methods
and devices. Pulse palpation to detect an irregular heart-
beat gave a high sensitivity (87% – 97%) but a moderate
to low specificity (71% – 81%) [11,15]. Although the spe-
cificity could possibly be improved by continued pulse
registration, but at the cost of decreasing sensitivity. The
Microlife BP monitor (Microlife Corporation, Taipei,
Taiwan), a modified sphygmomanometer that records
pulse intervals, gave a sensitivity of 100% and a specifi-
city of 90% (95% CI 87 – 92) when multiple measure-
ments were carried out [16]. Another study that also
used a modified sphygmomanometer showed a sensitiv-
ity of 95% (95% CI 93 – 98) and specificity of 86% (95%
CI 84 – 98) in a single measurement and a sensitivity of
97% (95% CI 91 – 99) and specificity of 89% (95% CI 85 –
92) on 3 measurements [17]. A finger probe that regis-
tered a pulse wave pattern for 30 seconds gave a sensitivity
of 100% and a specificity of 91% [18]. Two studies, similar
to the current study, also used a device that registered a
single-lead ECG in which the interpretation was done
afterwards by a primary care physician [17,19]. Somerville
et al. found a sensitivity of 96% (95% CI 80 – 100) and aspecificity of 98% (95% CI 91 – 100) [17], and Mant et al.
found a sensitivity of 85% (95% CI 79 – 91) and a specifi-
city of 86% (95% CI 85 – 88) with the use of a thoracic
lead and a sensitivity of 83% (95% CI 75 – 89) and a speci-
ficity of 89% (95% CI 87 – 90) with the use of a peripheral
lead [19]. The latter sensitivities and specificities were
moderate primarily due to the varying interpretation of
ECGs by primary care physicians. By contrast, the advan-
tage of the MyDiagnostick is the absence of an interpret-
ation bias.
This study was a phase II diagnostic study investigat-
ing the accuracy of the MyDiagnostick in a convenience
sample of healthy people and people with a history of
atrial fibrillation. However, before a clinical recommen-
dation on the use of the MyDiagnostick in every day
clinical practice can be given, a phase III diagnostic
study has to be performed, determining the clinical con-
sequences of introducing the MyDiagnostick through a
randomised trial. The place of the MyDiagnostick in
possible future screening programs for atrial fibrillation
therefore remains to be determined. The use of the
MyDiagnostick seems much more practical than electro-
cardiographic monitoring at home. It involves no skin
electrodes or wires and the use of the device does not
require any experience or medical knowledge. Further-
more, using the MyDiagnostick is faster and cheaper.
The MyDiagnostick also has an additional advantage in
comparison with a blood pressure monitor that detects
an irregular pulse, since every recording is registered
and the single-lead ECGs can be consulted later on to
confirm the red lights that the patient detected.
In terms of user friendliness, this screening tool is easily
manageable in the population aged 65 or older. The patient
only needs to hold the ends of the rod with both hands. The
unit goes on automatically, so that a visual limitation cannot
be a restricting factor. Furthermore, holding with the palm
of the hand up or down, holding it lightly or firmly, trem-
bling and physical activity during use do not seem to influ-
ence the accuracy and uniformity of the results.
In addition to detecting paroxysmal atrial fibrillation
and initiating the necessary treatment, the following ad-
vantages of future use could be hypothesized: following
up on the response to electroconversion and medical
treatment, improving compliance with therapy and po-
tentially decreasing medical costs (by means of the pre-
vention of ischemic CVA).
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This is the first study investigating the diagnostic accur-
acy of the MyDiagnostick in primary care. High sensitiv-
ities and specificities were obtained in the study
population, making this easy-to-use device a possible
candidate to implement in future screening or case-
finding programs for atrial fibrillation. However, a few
limitations of the current study should be mentioned.
First, a prevalence of atrial fibrillation of 6% was as-
sumed in subjects aged 65 and older. However, a variety
of prevalence figures is found in literature and is mainly
the result of differences in the study population, the
methods used (Holter, serial ECGs …) and the duration
of ECG recording. Second, several ECG devices were
used as the gold standard instead of one standardized
device. Third, the possible place of the MyDiagnostick in
a screening or case-finding strategy was not determined
with the current study, nor was a cost-benefit analysis of
a screening or case-finding strategy with the MyDiagnostick
done. And fourth, because the study population was a
convenience sample extrapolation of these results to
the general population should be made with caution.
Furthermore, investigations concerning the reliability of
the MyDiagnostick for other arrhythmias and test-retest
reliability must still be done.
Conclusion
The MyDiagnostick is an easy-to-use device that showed
a good diagnostic accuracy with a high sensitivity and
specificity for atrial fibrillation in a convenience sample
in primary care. Future research is needed to determine
the place of the MyDiagnostick in possible screening or
case-finding strategies for atrial fibrillation.
Abbreviations
CVA: Cerebrovascular accident; CI: Confidence interval;
ECG: Electrocardiogram; SD: Standard deviation; IQR: Inter-quartile range;
TIA: Transient ischaemic attack.
Competing interests
The author declares that they have no competing interests.
Authors’ contributions
BV, SS, KT, BT, DL drafted the manuscript. JD is responsible for the design,
conduct and analysis of the study. All authors participated in the critical
revision of the manuscript. All authors read and approved the final
manuscript.
Acknowledgements
The authors wish to thank the following general practitioners for contacting
patients and providing consultation rooms: Dr. K. Van der Veken, Dr. C. Van
Cauwenberge, Dr. K. Schelfaut, Dr. N. Van Den Haute, Dr. J. Cooreman, Dr. L.
Bontinck, Dr. R. Mechiels, Dr. K. Verhaegen, Dr. Z. De Aguirre, Dr. A. Van Hyfte,
Dr. F. Froyman, Dr. V. Heylen, Dr. L. Termote, Dr. M. Vandenheede, Dr. S.
Vandeputte, Dr. A. Verraes, Dr. K. Van Boeckel, Dr. L. Bruyninckx, Dr. L. Froyen,
Dr. B. Schoolmeesters, Dr. R. Schoolmeesters, Dr. G. Snijkers, Dr. K. Van Dael,
Dr. J. Gryffroy, Dr. L. Cras, Dr. F. Martens, Dr. C. Tack, Dr. L. Vanneste. We
would also like to thank the firm Applied Biomedical Systems BV for the
provision of the MyDiagnosticks.Author details
1Department of General Practice, Katholieke Universiteit Leuven (KUL),
Leuven, Belgium. 2Institute of Health and Society, Université Catholique de
Louvain (UCL), Brussels, Belgium. 3Department of Cardiology, Ziekenhuis Oost
Limburg, Genk, Belgium. 4Biomedical Research Institute, Faculty of Medicine
and Life Sciences, Hasselt University, Diepenbeek, Belgium.
Received: 1 February 2014 Accepted: 5 June 2014
Published: 9 June 2014References
1. Pérula-de-Torres LA, Martínez-Adell MA, González-Blanco M, Baena-Díez JM,
Martín-Rioboó E, Parras-Rejano JM, González-Lama J, Martín-Alvarez R,
Ruiz-Moral R, Fernández-García JÁ, Pérez-Díaz M, Ruiz-de-Castroviejo J,
Pérula-de-Torres C, Valero-Martín A, Roldán-Villalobos A, Criado-Larumbe M,
Burdoy-Joaquín E, Coma-Solé M, Cervera-León M, Cuixart-Costa L,
Collaborative Group DOFA-AP: Opportunistic detection of atrial
fibrillation in subjects aged 65 years or older in primary care: a
randomised clinical trial of efficacy. DOFA-AP study protocol.
BMC Fam Pract 2012, 13:13–106.
2. Miyasake Y, Barnes ME, Gersh BJ, Cha SS, Bailey KR, Seward JB, Iwasaka T,
Tsang TS: Coronary ischemic events after first atrial fibrillation: risk and
survival. Am J Med 2007, 120:357–363.
3. Wang TJ, Larson MG, Levy D, Vasan RS, Leip EP, Wolf PA, D'Agostino RB,
Murabito JM, Kannel WB, Benjamin EJ: Temporal relations of atrial
fibrillation and congestive heart failure and their joint influence
on mortality: the Framingham Heart Study. Circulation 2003,
107:2920–2925.
4. Morgan S, Mant D: Randomised trial of two approaches to screening
for atrial fibrillation in UK general practice. Br J Gen Pract 2002,
373:380.
5. Markides V, Schilling RJ: Atrial fibrillation: classification, pathophysiology,
mechanisms and drug treatment. Heart 2003, 89:939–943.
6. Camm J, Lip G, De Caterina R, Savelieva I, Atar D, Hohnloser SH, Hindricks G,
Kirchhof P, ESC Committee for Practice Guidelines(CPG): 2012 focused
update of the ESC Guidelines for the management of atrial fibrillation.
Eur Heart J 2012, 33:2719–2747.
7. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ:
Validation of clinical classification schemes for predicting stroke:
results from the National Registry of Atrial Fibrillation. JAMA 2001,
285:2864–2870.
8. Lip G, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ: Refining clinical risk
stratification for predicting stroke and thromboembolism in atrial
fibrillation using a novel risk facto-based approach: the Euro Heart
Survey on Atrial Fibrillation. Chest 2010, 137:263–272.
9. Wilson JMG, Jungner G: The principles and practice of screening for disease.
WHO Public Health papers. Geneva: World Health Organization; 1968.
10. Nieuwlaat R, Olsson SB, Lip G, Camm AJ, Breithardt G, Capucci A,
Meeder JG, Prins MH, Lévy S, Crijns HJ, Euro Heart Survey Investigators:
Guideline-adherent antithrombotic treatment is associated with
improved outcomes compared with undertreatment in high-risk patients
with atrial fibrillation: the Euro heart Survey on Atrial Fibrillation.
Am Heart J 2007, 153:1006–1012.
11. Harris K, Edwards D, Mant J: How can we best detect atrial fibrillation?
J R Coll Physicians Edinb 2012, 42(suppl 18):5–22.
12. MyDiagnostick: https://www.mydiagnostick.com/home-en.
13. Carley S, Dosman S, Jones SR, Harrison M: Simple nomograms to calculate
sample size in diagnostic studies. Emerg Med J 2005, 22:180–181.
14. Prineas R, Crow R, Blackburn H: The Minnesota Code Manual of
Electrocardiographic Findings. John Wright – PSG, Inc: Littleton MA; 1982.
15. Wiesel J, Abraham S, Messineo FC: Screening for asymptomatic atrial
fibrillation while monitoring the blood pressure at home: trial of regular
versus irregular pulse for prevention of stroke (TRIPPS 2.0). Am J Cardiol 2013,
111:1598–1601.
16. Wiesel J, Fitzig L, Herschman Y, Messineo FC: Detection of atrial fibrillation
using a modified microlife blood pressure monitor. Am J Hypertens 2009,
22:848–852.
17. Somerville S, Somerville J, Croft P, Lewis M: Atrial fibrillation: a comparison
of methods to identify cases in general practice. Br J Gen Pract 2000,
50:727–729.
Vaes et al. BMC Family Practice 2014, 15:113 Page 7 of 7
http://www.biomedcentral.com/1471-2296/15/11318. Lewis M, Parker D, Weston C, Bowes M: Screening for atrial fibrillation:
sensitivity and specificity of a new methodology. Br J Gen Pract 2011,
61:38–39.
19. Mant J, Fitzmaurice DA, Hobbs FD, Jowett S, Murray ET, Holder R, Davies M,
Lip GY: Accuracy of diagnosing atrial fibrillation on electrocardiogram by
primary care practitioners and interpretative diagnostic software: analysis
of data from screening for atrial fibrillation in the elderly (SAFE) trial.
BMJ 2007, 335:380.
doi:10.1186/1471-2296-15-113
Cite this article as: Vaes et al.: The diagnostic accuracy of the
MyDiagnostick to detect atrial fibrillation in primary care. BMC Family
Practice 2014 15:113.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
